The organization reportedly urged CMS and HHS to prohibit the policies in Medicare Advantage and exchange plans, according to a July 29 press release.
Avastin is used to treat patients with various vision-threatening diseases. Healthcare insurers began recommending biosimilars after ophthalmologists began having difficulties acquiring Avastin because the drug’s largest supplier, Optum, is currently unable to ship the drug.
AAO stated that the use of biosimilars puts patients’ safety at risk because, unlike Avastin, the drugs have not yet been tested in the eye.
“The Academy has told HHS and CMS it is inappropriate for plans to recommend or mandate use of these biosimilars for intravitreal injection without a prior clinical trial in eye disease and testing for retinal toxicity,” the organization said in the press release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.